Patent Application
20220259550
The present invention relates to a cellular component homogenate in liquid form, as well as to a cellular component homogenate in solid form, preferably as a freeze-dried or sprayed powder. Furthermore, the present invention relates to a homogenisation process for the preparation of said cellular component homogenate in liquid form and said cellular component homogenate in solid form, preferably as freeze-dried or sprayed powder. Lastly, the present invention relates to a composition comprising said cellular component homogenate in solid form and, optionally, one or more pharmaceutical or food grade or cosmetic additives and excipients, for use in the pharmaceutical, nutraceutical, medical devices, foods for special medical purposes, dietary supplements and food industry both in the human and veterinarian field, as well as for use in the cosmetics industry.
The techniques and methods of extraction of the various bacterial components present in bacteria, generally Gram-positive and Gram-negative on a large scale at industrial level still reveal many limits and drawbacks both in terms of the process methods used and in terms of the plant equipment used.
The limits and drawbacks still existing in the industrial production of bacterial components or bacterial extracts (more generally of lysates or bacterial homogenates) cause the product obtained, by means of partial or total breaking down of the cell wall following a whole cell processing, not to be functional (able to carry out its probiotic functional activity), not to be stable over time, well conserved under the operating conditions and processable for subsequent transformation into finished products, for example nutraceutical or cosmetic products. In addition, the product obtained ca be reproduced or standardised from a qualitative and quantitative point of view.
The technique for preparing a bacterial lysate, obtained through the lysis of whole cells mechanically, is affected by the preparation process used because the breaking down or lysis of the cell is carried out by means of a strong mechanical action carried out using mechanical stirrers or mixers or centrifuges.
During the research and development activity thereof, the Applicant was able to verify that when the partial or total breaking down, or lysis of the cells, is carried out mechanically, this type of breaking down or lysis is not able to preserve and conserve the bacterial components contained in the cells or belonging to the cells, in an optimal way, both from the productive point of view and from the point of view of metabolic activity and functional properties in terms of stability (stability over time and/or upon temperature change).
The partial or total breaking down or lysis of the cells is carried out mechanically through the direct contact of the liquid in which the cells, for example a bacterial biomass, are present and the mechanical cutting elements (rotating blades), or turbines or mixing blades, or centrifugation mills present in a mechanical stirrer or in a mixer or in a centrifuge.
The direct contact that occurs when the cells, contained in the bacterial biomass, are subjected to mechanical processing, for example, in a mechanical stirrer or mixer provided with stirring means (mixing knives or blades) or cutting means (cutting blades), which rotate at high rotation speeds, significantly affects the final product or bacterial lysate obtained, in terms of metabolic activity, functional properties and stability.
Furthermore, during the research and development activity thereof, the Applicant was able to verify that when said cell lysis is carried out through methods other than the mechanical one (for example, by means of a pressure homogenisation), the operating conditions are decisive toward producing a lysate or homogenate of bacterial strains capable of keeping the metabolic activity and the functional properties of the bacterial strains—from which said lysate or homogenate derives—intact, live and viable, and so that said activities and functionalities of the lysate or homogenate are stable over time and/or upon temperature change.
After a long and intense research and development activity, the Applicant developed a new process for the preparation of a homogenate or bacterial lysate which advantageously overcomes the aforementioned limits and drawbacks. In particular, provided through the process of the invention is a homogenate or bacterial strain lysate (liquid or solid) in which some components of the cell walls (for example, peptidoglycan or murein) of the bacterial strains subjected to the process maintain their structure (or three-dimensional structure) and thus their functionality. Furthermore, said components of the cell wall comprised in the lysate or homogenate (liquid or solid) obtained by the process of the invention are not bound to other cellular components and, therefore, they are capable of carrying out their metabolic and functional activity. Lastly, the structure and the amount of said components of the cell walls (e.g. peptidoglycan) included in the homogenate (liquid or solid) obtained by means of the process of the invention are stable over time (for example, from 1 to 6 months or 12 months) and upon temperature change (for example from 5° C. to 40° C.). In the light of the above, the process of the present invention provides a functional product comprising cell wall components of bacterial strains (e. g. peptidoglycan or murein) wherein said cell wall components are active, effective and stable over time.
Forming an object of the present invention is a process for the preparation of a cellular component homogenate in liquid form having the characteristics as defined in the attached claims.
Forming an object of the present invention is a process for the preparation of a cellular component homogenate in solid form, preferably as a freeze-dried or sprayed powder, having the characteristics as defined in the attached claims.
Forming an object of the present invention is a cellular component homogenate in liquid form having the characteristics as defined in the attached claims.
Forming an object of the present invention is a cellular component homogenate in solid form, preferably as a freeze-dried or sprayed powder, having the characteristics as defined in the attached claims.
Forming an object of the present invention is a composition comprising said cellular component homogenate in solid form (preferably as a freeze-dried or sprayed powder) and, optionally, one or more pharmaceutical or food grade additives and excipients, for use according to the attached claims.
Preferred embodiments of the present invention will be described in greater detail hereinafter without wishing to limit the scope of the present invention in any manner whatsoever.
The terms “sprayed” or “spraying” can be used as nouns or adjectives related to a spraying step.
The term “room temperature” indicates a temperature comprised from 15° C. to 35° C., preferably from 20° C. to 30° C., even more preferably at about 25° C.
The Applicant found it useful to develop a new process (
Said cell homogenate in liquid form (OMO1), obtained from said homogenisation process (POMO1), is then subjected to a further processing process (POMO2) which provides for a step in which the freeze-drying or spraying of said OMO1 is carried out, optionally preceded by a cryoprotection step, to obtain a homogenate (OMO2) in a freeze-dried or sprayed solid form (powder), preferably sprayed.
Said freeze-dried or sprayed homogenate (OMO2) in solid form (powder) obtained from said processing process (POMO2), is then used in mixture with at least one or more pharmaceutical or food grade or cosmetic additives and excipients, to obtain a product for use in the pharmaceutical, nutraceutical, medical devices (EU Reg. 2017/745), foods for special medical purposes (FSMPs), dietary supplements and food industry both in the human and veterinarian field, as well as for use in the cosmetics industry.
According to a first embodiment (in short FR-I), the process for the preparation of a cellular component homogenate in liquid form (homogenisation process (POMO1) subject of the present invention) schematically provides for:
The industrial fermentation step is preceded by a step in which the bacterial cell strain to be subjected to homogenisation is first activated/revived after thawing the respective cryovial. The cryovials of the WCB (working cell bank) of said strain are collected from the freezer and inoculated in anaerobiosis in a test tube, for example measuring about 15 ml, in the medium provided for by the protocol (variable from strain to strain) at an appropriate temperature (range 32° C.-37° C.). Growth steps are carried out in test tube, sterile disposable Petri dish and in a conical flask to obtain the laboratory stock culture to be fermented.
The stock culture is then subjected to a fermentation step. The industrial fermentation phase is carried out by using methods, fermentation media and equipment known to the man skilled in the art of fermentations of lactic bacteria and bifidobacteria or other genus of anaerobic bacteria.
Obtained at the end of the industrial fermentation step is a bacterial biomass in liquid form which, once produced, is preferably concentrated by means of techniques and equipment known to the man skilled in the art (for example, continuous discharge or discontinuous loading centrifuges, filtration systems) by a factor of 5-20, preferably 10, with respect to the concentration of the cells used in the fermentation step, to obtain a concentrated bacterial biomass. If, for example, at the end of the step in which the fermentation takes place there is a fermented biomass having a concentration of bifidobacteria or lactic bacteria or other genus of anaerobic bacteria (in live and viable form) from 1×109 AFU to 50×109 AFU, preferably of about 10×109 AFU, at the end of the step in which the biomass is concentrated, there will be a biomass concentration from 10×109 AFU to 500×109 AFU, preferably from 50-200×109 AFU, more preferably 100×109 AFU. The concentration step is carried out with continuous discharge centrifuges at room temperature.
The concentrated bacterial biomass of bifidobacteria or lactic bacteria or other genus of anaerobic bacteria (in live and viable form) is then preferably washed to obtain a washed and concentrated bacterial biomass of the bacterial strain in question. The washing step is carried out with sterile water cooled at a temperature comprised from 5° C. to 45° C., preferably from 10° C. to 25° C., to obtain a concentrated and washed biomass of said bacterial cell strain.
The washed and concentrated bacterial biomass is in liquid form and it contains live and viable cells, it is a biomass that is stable and reproducible from an industrial point of view and in terms of functional properties and activities.
The washed and concentrated bacterial biomass has a bacterial concentration, for example in the order of 100 billion (100-200×109) and it contains—therein—for example water, fermentation residues, elements of the medium of choice for the growing bacterial strain, the release factors of the bacterial strain itself (postbiotic factors).
The washed and concentrated bacterial biomass exiting from the fermentation step having a temperature comprised from 10° C. to 35° C., preferably from 20° C. to 25° C., is supplied, for example by means of a pipe and a volumetric pump, flowing into a collection tank and subsequently transferred to the industrial homogenises.
According to a second embodiment (in short FR-II), the process for the preparation of a cellular component homogenate in liquid form (homogenisation process (POMO1) subject of the present invention) schematically provides for:
For example, according to the second embodiment (FR-II), one of the freeze-dried bacterial strains of the Probiotical collection is resuspended in drinking water or physiological solution at room temperature in an industrial dissolver to obtain a concentrated biomass from 100×10{circumflex over ( )}9 to 300×10{circumflex over ( )}9, preferably 200×10{circumflex over ( )}9. In said first embodiment (FR-I) and in said second embodiment (FR-II) the homogenisation step takes place under similar conditions to obtain a cellular component homogenate in similar liquid form.
The industrial homogeniser (
In the homogenisation step, the cell wall is broken down solely and exclusively using the operating pressure, which is exerted on a portion of the biomass volume (for example a volume from 10 litres to 100 litres) and not by means of a mechanical breaking down using metal cutting parts, or turbines, or mixing blades, or centrifugation mills.
The pressure homogenisation step applied to the concentrated and washed biomass according to FR-I or to the biomass according to FR-II is able to determine the breaking down of the bacterial wall and micronize the particles of the treated product (cells present in the biomass) in order to improve the mixing and stability thereof. In other words, the homogenisation step carried out with a pressure homogeniser allows to make the cellular components—such as for example the cell wall or the components of the cell wall—present in the biomass cells homogeneous. An emulsion biomass (homogenate in liquid form) is obtained with a high degree of suspension and dispersion in which the micronized particles (the cellular components, for example peptidoglycan) are stable (with time and/or upon temperature change) and uniform. Preferably, said biomass has a density comprised from 1.02 to 1.10 weight/volume.
One type of industrial pressure homogeniser that can, for example, be used in the context of the present invention is of the 3 plunger type, with rear cooling chamber, positioned on the rear part of the compression head. Housed in the compression head are the plungers, whose task is to pump the biomass under pressure (for example, product input pressure: 3-4 bar), the intake and delivery valves, and the homogeniser valve (
Said primary pressure is comprised in a range from 1200 bar to 2000 bar, preferably from 1500 or 1600 bar to 2000 bar. Said primary pressure is also defined as the “operating pressure” being the higher pressure exerted during the homogenisation step.
Said secondary pressure is comprised in a range from 50 bar to 200 bar, preferably from 100 bar to 150 bar.
One type of homogeniser may have, for example, a supply pressure of about 3-4 bar, a supply flow rate of about 1500-2500 L/hour and an operating pressure up to about 2000 bar.
For example, a type of homogeniser that can be used in the context of the present invention may have the following specifications:
1. flow rate range 1000-2000 litres/hour;
2. primary pressure range: 1600-2000 bar;
3. secondary pressure range: 100-150 bar;
4. condensate temperature range: 45° C.-65° C.;
5. Water pressure range: 2.5-3.5 bar (for vapour condensation);
6. product input pressure range: 3-4 bar.
The two pressures, the primary and the secondary, are exerted in line and both are fundamental for the optimal homogenisation of the product: as a matter of fact, pressure shocks obtained at different pressures with respect to each other are needed to improve the homogenisation. The homogenisation step with the relative pressures is set at the beginning of the first cycle and it remains stable and unchanged throughout the homogenisation process during the processing steps, which can vary from strain to strain.
The homogenisation step comprises a number of processing cycles or steps comprised from 1 to 10 for the total volume of the biomass, preferably from 4 to 8, even more preferably from 3 to 6. The homogenisation step is carried out over a period of time which depends on the number of cycles or steps carried out on the biomass and on the type of homogeniser (flow rate in litres/hour and operating pressure in Kg/cm2 or bar) used. For example, when processing of 1000 litres of biomass in a pressure homogeniser having a flow rate of 2000 litres/hour and an operating pressure of 2000 bar, a processing cycle or step will last about 0.5 hours. If the homogenisation step provides for 6 cycles, the homogenisation step of 1000 litres of biomass is carried out in 3 hours.
The expression processing cycle or step is used to indicate that the whole volume of the concentrated and washed bacterial biomass according to FR-I or of the biomass according to FR-II flowing into the homogeniser is subjected to a pressure homogenisation, homogenization carried out on n portions of said total volume of said biomass (for example, volume portion from 10 ml to 100 ml) in a dynamic continuous process as in
Once a volume portion of said biomass has been pressure homogenised, this portion is continuously transferred and collected in a temperature-controlled container (collection tank). Once the whole volume of said biomass has been pressure homogenised, a processing cycle or step is completed. A processing cycle or step will be considered completed once the whole biomass volume will have been collected in said container at a controlled temperature. The temperature of the homogenised biomass exiting from the homogeniser and entering into said container is comprised from 15° C. to 35° C., preferably from 20° C. to 30° C., even more preferably at about 25° C. The temperature of the homogenised biomass in said container (collection tank) is comprised from 5° C. to 20° C., preferably from 10° C. to 15° C. Once the whole biomass volume has been pressure homogenised and collected in said container (collection tank) at the end of a cycle, the volume is once again supplied back into said homogeniser to carry out a further processing cycle or step under the same operating conditions as the previous cycle. Therefore, the whole volume of said biomass will be cyclically supplied to said homogeniser in a number of times equal to the number of cycles or steps established for a given bacterial strain.
At the end of each processing cycle or step a sample of homogenised biomass is taken from said container (collection tank) at a controlled temperature (temperature 5°−20° C. or 10° C.-15° C.) and subjected to a cytofluorimetric reading (cytofluorimetry) by means of a cytofluorimeter to determine the membrane integrity reading value (as the value of cells not lysed by the pressure homogenisation), a value preferably comprised from 0.05% or 1% to 10% (for example, 0.01%, 0.5%, 1.5%, 2%, 2.5%, 3%, 4%, 5%, 6%, or 8%) of the initial membrane integrity value of the concentrated and washed biomass according to FR-I or of the biomass according to FR-II. Such membrane integrity value is the optimal range that allows to obtain a plate growth comprised from 1% to 0.01%, preferably of about 0.1%. For example, if the concentration of bacteria with an intact membrane of the concentrated and washed biomass at the inlet of the homogeniser is about 100×109 AFU, at the end of the homogenisation steps, there for example will be (1%) equal to 1×109 AFU, so as to have a plate count equal to 1×106 CFU (0.1% with respect to the cytofluorimetric reading after homogenisation).
By way of example, added hereto is
Table 1 refers to
In tables 1 and 2 and in
Q3-1: membrane integrity initial value of the concentrated and washed biomass prior to the pressure homogenisation step;
Q3-2: damaged cell value
Q3-2: cellular component value
Q3-2: dead cell value
The homogenisation step ends upon reaching said membrane integrity value comprised from 0.1% or 1% to 10%, preferably from 0.5% to 6%, more preferably from 1% to 3%, of the initial value of the concentrated and washed biomass according to FR-I or of the biomass according to FR-II.
At the end of the homogenisation step and, therefore, at the last processing cycle or step of the whole biomass volume, all the homogenised biomass will be present in said collection container at controlled temperature (temperature 5°−20° C. or 10° C.-15° C.).
The concentrated, washed and homogenised bacterial biomass (or biomass at the end of the homogenisation step) is in liquid form and it therein contains cell wall fragments, such as glycoproteins, phospholipids, murein (or peptidoglycan) and all intracellular components such as for example DNA, ribosomes and proteins.
Murein (also known as peptidoglycan or bacterial mucopeptide) is a polymer that represents an essential component of the cell wall of bacteria being the main factor responsible for the cell integrity. The bacterial classification resulting from Gram staining is based on the different composition of the wall made of murein. It is therefore well known that murein is a fundamental component of the bacterial wall and it is found both in Gram-positive and in Gram-negative, but in different proportions. It is very abundant in Gram+ (90% of the wall) and less abundant in Gram− (10% of the wall). In the context of the present invention the terms “murein” and “peptidoglycan” are used as synonyms of the same substance.
The concentrated, washed and homogenised bacterial biomass (or biomass at the end of the homogenisation step) of bifidobacteria or lactic bacteria or other genus of anaerobic bacteria represents the cellular component homogenate in stable and reproducible liquid form (OMO1), subject of the present invention.
Said cellular component homogenate in stable and reproducible liquid form (OMO1), obtained from said homogenisation process (POMO1) (according to said FR-I or FR-II), is then subjected to a further processing process (POMO2), which provides for a step in which freeze-drying or spraying (preferably a spraying step) is carried out, possibly (optionally) preceded by a step in which a cryoprotection (cryoprotection step) is carried out to obtain a freeze-dried or sprayed homogenate in solid form (OMO2) —FIG. 1. Thus, said homogenate in a freeze-dried or sprayed solid form can derive from a process according to the invention (POMO1 and POMO2) comprising or not comprising a cryoprotective step.
Basically, according to an aspect of the invention, the concentrated, washed and homogenised bacterial biomass or biomass at the end of the homogenisation step (in short, the homogenised biomass) is subjected to a cryoprotection step using standard cryoprotectants in use, such as for example polysaccharides, such as for example sugars, preferably sucrose alone or in admixture, for example, with sodium, potassium, calcium or magnesium salts of phosphoric acid.
Said cryoprotection step provides for that the cryoprotectant in liquid form, prepared and previously cooled (temperature from 5° C. to 15° C., preferably about 10° C.), be added, at a concentration comprised from 5% to 40% by weight with respect to the weight of the homogenised biomass in liquid form, preferably equal to about 20%, for transfer under overpressure (pressure from 0.5 bar to 1.5 bar) from the cryoprotectant container to the homogenised biomass in liquid form in the container at a temperature comprised from 5° to 20° C., preferably about 10° C., to obtain a homogenised and cryoprotected biomass.
At the end of the cryopreservation step, the homogenised and cryoprotected biomass, still in liquid form, is subjected to a subsequent freeze-drying or spraying step, preferably spraying step, to obtain a biomass in solid form having a concentration for example 10-15 times (for example 3, 5, 8, or 12 times) more concentrated than the biomass (according to FR-I or according to FR-II) entering the homogenises.
If, for example, at the end of the step in which the biomass concentration is achieved (according to FR-I) there is a concentrated biomass having a concentration of bifidobacteria or lactic bacteria or other genus of anaerobic bacteria (in live and viable form) of about 100×109 AFU, at the end of the freeze-drying or spraying step, there will be a component homogenate in solid form OMO2 (powder) which therein contains cell wall fragments, such as for example glycoproteins, phospholipids and peptidoglycan (murein) and all intracellular components, such as for example DNA, ribosomes and proteins.
In this case (both in the presence and in the absence of the cryoprotection step) an amount of murein (or peptidoglycan) comprised from 5% to 40% by weight, preferably from 10% to 30% by weight, even more preferably from 15% to 25% by weight with respect to the weight of the freeze-dried or sprayed sample (homogenate in solid form of the present invention) can be obtained.
Said homogenate in solid form of the present invention (obtained from the process of the present invention according to FR-I or FR-II and from said step of pressure homogenisation step and subsequent freeze-drying or spraying step) comprises murein (or peptidoglycan) at an initial amount (for example, at a percentage by weight comprised from 5% to 40%, preferably from 10% to 30%, more preferably from 15% to 25%, with respect to the weight of the homogenate in solid form) predominantly constant over time (for example from 1 month to 5 years or from 6 months to 3 years or 12 months to 24 months) and/or upon temperature change (for example, from 0° C. to 50° C., preferably from 5° C. to 40° C., more preferably from 15° C. to 35° C.). Furthermore, said murein (or peptidoglycan) comprised in said homogenate in liquid form and/or in solid form maintains its structure stable (over time and/or upon temperature change), it is mainly not bound to other cellular components and, therefore, it is able to exert a metabolic and functional activity. For example, it can be assumed that, following homogenisation, there be formed cell wall parts to which the peptidoglycan chains remain complexed and act as activators.
The term “constant” or “prevalently constant,” referring to the amount of peptidoglycan comprised in said homogenate, means that the amount (for example, amount by weight) of peptidoglycan present in the homogenate at the end of the pressure homogenisation step (in short, initial amount of peptidoglycan) remains approximately constant in a time range with a possible change of said amount at a percentage comprised from 0.5% to 10% (for example, 1%, 2%, 3%, 4%, 5%, 6% or 8%) with respect to 100% of the amount.
Freeze-drying and spraying are carried out using methods and equipment known to the man skilled in the art.
For example, spraying can be carried out with an spray dryer normally used for the spraying and drying liquid suspensions with a protocol which provides for an input temperature of the drying air of about 150° C.-180° C. and an output temperature of about 70° C.-90° C.
In an embodiment, the cellular component homogenate in solid form OMO2 (freeze-dried or sprayed powder) is used in a manner such to be mixed with one or more pharmaceutical or food grade or cosmetic additives to obtain a composition which can be advantageously used in the production of finished products in the pharmaceutical, nutraceutical, medical devices, food for special medical purposes, supplements and food industry for both human and veterinary purposes, as well as for use in the cosmetic industry.
Aspects of the present invention according to the first embodiment FR-I are reported below (FR-I-no): FR-I-1. A process for preparing a cellular component homogenate in liquid form comprising the following steps:
FR-I-2. The process according to FR-I-1, wherein said step for fermenting said laboratory stock culture to obtain a fermented biomass is carried out up to reaching a bacterial cell concentration comprised from 1×107 to 1×109 AFU, preferably 1×108 AFU, measured using a cytofluorometry method, in the fermented biomass.
FR-I-3. The process according to FR-I-1, wherein said step for concentrating said fermented biomass containing said bacterial cell strain is obtained by a factor equal to 10 times, with respect to the bacterial cell concentration comprised from 1×106 to 1×1010 AFU, preferably from 1×107 and 1×109 AFU, even more preferably 1×109 AFU, measured using a cytofluorometry method, present in the fermented biomass.
FR-I-4. The process according to FR-I-1, wherein said step of subjecting said concentrated biomass to a homogenisation step is carried out in a pressure homogeniser having, preferably a supply flow rate comprised from 1000 to 2000 litres/hour and an operating pressure, during the homogenisation of said biomass, comprised from 1000 bars to 2000 bars, for each working cycle or step.
FR-I-5. The process according to FR-I-4, wherein said homogenisation step is carried out after completing a number of processing cycles or steps comprised from 1 to 10, preferably from 4 to 8, even more preferably from 3 to 6.
FR-I-6. A cellular component homogenate in liquid form obtained according to the process according to any one of FR-I-1-5.
FR-I-7. A process for preparing a cellular component homogenate in solid form, wherein said process comprises a further step for subjecting said cellular component homogenate in liquid form obtained according to the process according to any one of FR1-FR5 to a cryoprotection step wherein a cryoprotectant solution in liquid form containing at least one sugar, preferably sucrose, and at least one sodium, potassium, calcium or magnesium salt of phosphoric acid, is added to said homogenate to obtain a cryoprotected homogenate.
FR-I-8. The process for preparing a cellular component homogenate in solid form, preferably a freeze-dried or sprayed powder, according to FR-I-7, wherein said cryoprotected homogenate in liquid form is subjected to a further freeze-drying or spraying step to obtain a cellular component homogenate in solid form.
FR-I-9. A cellular component homogenate in solid form, preferably freeze-dried or sprayed powder obtained according to the process according to FR-I-7 or FR-I-8, wherein said homogenate contains murein at an amount comprised from 5% to 40% by weight, preferably from 10% to 30% by weight, even more preferably from 15% to 25% by weight, with respect to the weight of the homogenate.
FR-I-10. A composition comprising said cellular component homogenate in solid form according to FR-I-9 and, optionally, one or more pharmaceutical or food grade or cosmetic additives and excipients, for use in the pharmaceutical, nutraceutical, medical devices, foods for special medical purposes, dietary supplements and food industry both in the human and veterinarian field, as well as for use in the cosmetics industry.
Study of stability over time at different temperatures of homogenates in solid form of cellular components of strains of bacteria obtained according to the process of the present invention (hereinafter, solid homogenates).
In the present experimental study, stability over a one-year time range at different temperatures was evaluated (stability at: 40° C. at 0, 1, 2, 3, 6 and 12 months; at 25° C. at 0, 3, 6 and 12 months and at 5° C. at 0, 3, 6 and 12 months) of said solid homogenates (obtained according to FR-I or FR-II).
In particular, the stability study was carried out on samples obtained from homogenised bacterial strains in liquid phase according to FR-II and then sprayed (not freeze-dried), without addition of phosphates and without cryoprotection.
Solid homogenates obtained from strains of bacteria belonging to different genera and species were analysed according to Table A. The stability results do not vary considerably with the variation of the genus and species to which the strains belong. The stability data of two samples of representative bacteria strains (in short, test samples or Sample 1 and Sample 2) expressed as the amount (weight/weight percentage) of murein (peptidoglycan) present in each test sample are reported below.
An enzymatic mixture and the addition of chemical additives for the digestion of the cellular components, except for the peptidoglycan of interest (i.e. murein), were used for the isolation and quantification of the murein in the samples under analysis. The quantification (in triplicate) took place following gravimetric separation of murein from the undesired cellular components.
I. Time zero (t0)
Table 3 shows the results of gravimetric quantitation of the murein of the 2 samples analysed (mean value of 3 replicates), starting from 500 mg of sample at time zero (t0 immediately after completing the pressure homogenisation step)
II. Time 1 Month (t1)
Table 4 shows the results of gravimetric quantitation of the murein of the 2 samples analysed (mean value of 3 replicates), starting from 500 mg of sample after 1 month (t1) at about 40° C.
III. Time 2 Months (t2)
Table 5 shows the results of gravimetric quantitation of the murein of the 2 samples analysed (mean value of 3 replicates), starting from 500 mg of sample after 2 months (t2) at about 40° C.
IV. Time 3 Months (t3)
Table 6 (and
V. Time 6 Months (t6)
Table 6 (and
VI. Time 12 Months (t12)
Table 8 (and
In a time range of 12 months, the quantitation of murein isolated from the two samples of solid homogenate of cellular components of strains of bacteria obtained by the process of the present invention is al-most constant at the three tested temperatures (40° C., 25° C. and 5° C.).
Lactobacillus casei
Lactobacillus gasseri
Lactobacillus crispatus
Lactobacillus fermentum
Lactobacillus fermentum
Lactobacillus casei
Streptococcus thermophilus
Streptococcus thermophilus
Lactobacillus pentosus
Lactobacillus plantarum
Lactobacillus plantarum
Lactobacillus plantarum
Lactobacillus plantarum
Lactobacillus casei
Lactobacillus belonging to the
acidophilus group 192A/1 aiai
Bifidobacterium longum
Bifidobacterium breve
Bifidobacterium lactis
Lactobacillus plantarum
Lactococcus lactis ssp.
lactis 501/4 ci
Lactococcus lactis ssp.
lactis 501/4 hi
Lactococcus lactis ssp.
lactis 501/4 ci
Lactobacillus plantarum
Lactobacillus acidophilus
Lactobacillus paracasei
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Bifidobacterium adolescentis
Bifidobacterium adolescentis
Bifidobacterium breve
Bifidobacterium
pseudocatenulatum
Bifidobacterium
pseudocatenulatum
Bifidobacterium longum
Bifidobacterium breve
Lactobacillus casei
Lactobacillus delbrueckii
Lactobacillus delbrueckii
Staphylococcus xylosus
Bifidobacterium adolescentis
Lactobacillus plantarum
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Lactobacillus fermentum
Lactobacillus fermentum
Lactobacillus fermentum
Lactobacillus fermentum
Lactobacillus gasseri
Lactobacillus gasseri
Lactobacillus gasseri
Lactobacillus gasseri
Bifidobacterium adolescentis
catenulatum sp./
pseudocatenulatum
Bifidobacterium adolescentis
Bifidobacterium adolescentis
animalis subsp. lactis
Bifidobacterium catenulatum
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Weissella ssp. WSP 01
Weissella ssp. WSP 02
Lactobacillus ssp. WSP 03
Lactobacillus plantarum
Lactobacillus plantarum
Lactococcus lactis
Lactobacillus fermentum
Lactobacillus fermentum
Lactobacillus casei
Bifidobacterium bifidum
Lactobacillus delbrueckii
Lactobacillus delbrueckii
Lactobacillus delbrueckii
Lactobacillus delbrueckii
Lactobacillus delbrueckii
Bifidobacterium
pseudocatenulatum
Lactobacillus acidophilus
Lactobacillus paracasei
Lactobacillus pentosus
Lactobacillus rhamnosus
Lactobacillus delbrueckii
Lactobacillus plantarum
Lactobacillus salivarius
Lactobacillus salivarius
Bifidobacterium bifidum
Bifidobacterium bifidum
Bifidobacterium bifidum
Bifidobacterium lactis
Lactobacillus acidophilus
Lactobacillus brevis
Bifidobacterium animalis
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium bifidum
Bifidobacterium breve
Bifidobacterium lactis
Lactobacillus reuteri
Lactobacillus reuteri
Lactobacillus reuteri
Lactobacillus reuteri
Lactobacillus paracasei
Lactobacillus acidophilus
Bifidobacterium bifidum
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus paracasei
Lactobacillus salivarius
Lactobacillus gasseri
Lactobacillus acidophilus
Lactobacillus salivarius
Lactobacillus crispatus
Lactobacillus crispatus
Lacotbacillus acidophilus
Lactobacillus gasseri
Lactobacillus paracasei
Bifidobacterium infantis
Bifidobacterium bifidum
Bifidobacterium longum
Bifidobacterium lactis
Bifidobacterium longum
Bifidobacterium breve
Bifidobacterium breve
Bifidobacterium breve
Bifidobacterium longum
Lactobacillus salivarius
Lactobacillus reuteri
Lactobacillus reuteri
Lactobacillus reuteri
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Lactobacillus salivarius
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium longum
Lactobacillus johnsonii
Lactobacillus rhamnosus
Lactobacillus rhamnosus
Lactobacillus reuteri
Lactobacillus reuteri
Lactobacillus reuteri
Bifidobacterium longum
Bifidobacterium infantis
Lactobacillus plantarum
Bifidobacterium longum
Bifidobacterium longum
Lactobacillus salivarius
Lactobacillus salivarius
Lactobacillus pentosus
Bifidobacterium pseudolongum
Lactobacillus fermentum
Lactobacillus fermentum
Lactobacillus casei
Lactobacillus crispatus
Lactobacillus jensenii
Lactobacillus helveticus
Lactobacillus helveticus
Lactococcus lactis ssp.
Lactococcus lactis ssp.
Lactococcus lactis ssp.
Bifidobacterium longum
Bifidobacterium longum
Bifidobaterium animalis
Streptococcus thermophilus
Bifidobacterium infantis
Bifidobacterium infantis
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Lactobacillus fermentum
Lactobacillus fermentum
Leuconostoc sp.
Leuconostoc sp.
Leuconostoc sp.
Leuconostoc sp.
Lactobacillus plantarum
Lactobacillu splantarum
Lactobacillus plantarum
Lactobacillus plantarum
Lactobacillus pentosus
Lactobacillus reuteri
Lactobacillus brevis
Lactobacillus salivarius
Bifidobacterium breve
Lactococcus lactis
Bifidobacterium longum
Lactobacillus rhamnosus
Lactobacillus kefiri
Lactobacillus kefiri
Lactobacillus acidophilus
Lactobacillus kefiranofaciens
Lactobacillus kefiri
Lactobaciullus kefiri
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Streptococcus thermophilus
Lactobacillus salivarius
Weissella confusa
Weissella confusa
Lactobacillus curvatus
Lactobacillus plantarum
Lactobacillus reuteri
Lactobacillus parasei
Lactobacillus reuteri
Lactobacillus rhamnosus
Lactobacillus rhamnosus
Lactobacillus paracasei
Lactobacillus reuteri
Lactobacillus rhamnosus
Lactobacillus fermentum
Lactobacillus fermentum
Lactobacillus fermentum
Bifidobacterium animalis
Bifidobacterium animalis
Lactobacillus gasseri
Lactobacillus helveticus
Bifidobacterium adolescentis
Bifidobacterium bifidum
Bifidobacterium bifidum
Bifidobacterium longum
Bifidobacterium longum
Bifidobacterium adolescentis
Lactobacillus casei
Bifidobacterium bifidum
Lactobacillus plantarum
Lactobacillus fermentum
Lactobacillus crispatus
| Number | Date | Country | Kind |
|---|---|---|---|
| 102019000013356 | Jul 2019 | IT | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IB2020/057205 | 7/30/2020 | WO |
